Key result
Recombinant coxsackievirus CVB3/IFN-gamma was evaluated as a vaccine in a murine model of CVB3-induced myocarditis to assess the effects of administration route, age, and pre-existing immunity.
This preclinical study investigated the protective capability of a recombinant CVB3/IFN-gamma vaccine in a murine model of CVB3-induced myocarditis.
Does not support clinical use in myocarditis; hypothesis-generating for recombinant CVB3/IFN-gamma vaccines in animal models.
Several different procedures have been developed to deliver essential genes to an organism by viral vectors. Some reports have already been published demonstrating the potential to use enteroviruses as transfer vehicles. One application of these viral vectors is the organ-specific expression of immunoregulatory cytokines. It has been shown previously that local expression of interferon-gamma (IFN-gamma) by the recombinant coxsackievirus CVB3/IFN-gamma conferred protection against virus-caused disease via direct and indirect mechanisms. Using a murine model of CVB3-induced myocarditis, other aspects of the CVB3/IFN-gamma application as a vaccine were studied concerning route of administration, age, and presence of a pre-existing immune response.
No takes yet. Share an insight, caveat, or question.
Henke et al. (2008) studied CVB3-induced myocarditis. Recombinant coxsackievirus CVB3/IFN-gamma was evaluated on Vaccine efficacy concerning route of administration, age, and pre-existing immune response. Recombinant coxsackievirus CVB3/IFN-gamma was evaluated as a vaccine in a murine model of CVB3-induced myocarditis to assess the effects of administration route, age, and pre-existing immunity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: